IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of   Docket No: Q71975

Levon ARAKELYAN, et al.

U.S. Patent Appln. No.: 10/662,345   Group Art Unit: 1631

Confirmation No.: 2068   Examiner: Lori A CLOW

Filed: September 16, 2003

For: A METHOD FOR OPTIMIZING THE EFFICACY OF CLINICAL TRIALS DURING
        DRUG DEVELOPMENT

STATEMENT OF SUBSTANCE OF INTERVIEW

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

        Please review and enter the following remarks summarizing the interview conducted on

January 5, 2011:

REMARKS

        An Examiner's Interview Summary Record (PTO-413) was mailed January 10, 2011.

        During the interview, the following was discussed:

        1.   Brief description of exhibits or demonstration: None

        2.   Identification of claims discussed: None

        3.   Identification of art discussed: Rooney *et al.*

        4.   Identification of principal proposed amendments: None

        5.   Brief Identification of principal arguments: None

6.   Indication of other pertinent matters discussed: The potential differences between the prior art of Rooney *et al.* and the instantly claimed invention were discussed.

7.   Results of Interview: The Examiner agreed to review Rooney *et al.* in light of the discussion.

It is respectfully submitted that the instant STATEMENT OF SUBSTANCE OF INTERVIEW complies with the requirements of 37 C.F.R. §§1.2 and 1.133 and MPEP §713.04.

It is believed that no petition or fee is required. However, if the USPTO deems otherwise, Applicant hereby petitions for any extension of time which may be required to maintain the pendency of this case, and any required fee, except for the Issue Fee and the Publication Fee, for such extension is to be charged to Deposit Account No. 19-4880.

Respectfully submitted,

/Tu A. Phan/

SUGHRUE MION, PLLC   Tu A. Phan, Ph.D.
Telephone: (202) 293-7060   Registration No. 59,392
Facsimile: (202) 293-7860

WASHINGTON OFFICE
23373
CUSTOMER NUMBER

Date: February 10, 2011